U.S., Nov. 26 -- ClinicalTrials.gov registry received information related to the study (NCT07249320) titled 'Evaluating ABRYSVO Maternal Vaccine Effectiveness Among Infants' on Nov. 18.
Brief Summary: To generate critical evidence to support vaccine policy and implementation, Pfizer will collaborate with Kaiser Permanente Northern California (KPNC) to study the vaccine effectiveness (VE) of ABRYSVO vaccination during pregnancy in a real-world population. The overall research question of this study is: what is the effectiveness of ABRYSVO vaccination during pregnancy against medically-attended (MA) RSV-associated and all-cause infant outcomes in a large, diverse, real-world population? This study will use a retrospective cohort design and w...